synthesis of cytochrome C oxidase 1Genealiases: MC4DN4 · SCOD1
Q-omics provides the consensus-scored SCO1 profile across patient tissues and cancer cell-line models. SCO1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SCO1 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, SCO1 RNA expression shows 19,655 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, HNSC, and UVM as cancer lineages where SCO1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SCO1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SCO1 survival associations across molecular data types. SCO1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SCO1 RNA expression–survival associations across cancer types. High SCO1 expression shows unfavorable associations in MESO, LUAD, LGG and LUSC, but favorable associations in KIRC and READ. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for SCO1 RNA expression.
This table summarizes SCO1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SCO1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SCO1 shows lower tumor expression in THCA, KIRC, COAD, KICH and BRCA and higher tumor expression in HNSC. The HNSC box plot shows higher SCO1 RNA expression in tumor versus normal tissue (log2 FC = +0.491, t-test p < 0.001).
This table shows molecular features associated with SCO1 in patient tissues and cancer cell lines. In patient samples, SCO1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SCO1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and SOFT_TISSUE.
